Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hydroxypropyl Guar Galactomannan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AL-43546 0.15% |
| 2 | EXPERIMENTAL | AL-43546 0.25% |
| 3 | ACTIVE_COMPARATOR | AL-43546 0%(Vehicle) |
| 4 | ACTIVE_COMPARATOR | 0.1% sodium hyaluronate ophthalmic solutio |
| Name | Type | Description |
|---|---|---|
| Hydroxypropyl Guar Galactomannan | DRUG | One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods. |
| 0.1% sodium hyaluronate ophthalmic solution | DRUG | One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods. |
Inclusion Criteria: * Subjects with NIBUT of either eye is 8 seconds or less and other eye is 10 seconds or less at screening test and NIBUT of either eye before instillation in Period I is 10 seconds or less. Exclusion Criteria: * Diagnosis of severe Sjogren's syndrome (history of the use of pun...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | ABBV-444, REFRESH OPTIVE UD |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Alcon AG | ALC | 1 | N/A | Undisclosed |
| Harrow, Inc. | HROW | 1 | - | Undisclosed |
Hydroxypropyl Guar Galactomannan is an investigational small molecule being developed for Dry Eye Disease. It is in Phase 2 clinical development, meaning it has not yet been approved and remains under study to evaluate its safety and effectiveness for this condition.
Hydroxypropyl Guar Galactomannan is being developed by Alcon Inc., a company traded on the stock exchange under the ticker ALC. Alcon is conducting clinical research on this drug candidate for the treatment of Dry Eye Disease.
Hydroxypropyl Guar Galactomannan is in Phase 2 clinical development. It is an investigational drug, not yet approved, and is being studied for its potential use in treating Dry Eye Disease. One Phase 2 trial has been completed.
Hydroxypropyl Guar Galactomannan has one completed Phase 2 clinical trial registered as NCT00760045. This study, titled "Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time," enrolled 40 participants in Japan.
Yes, Hydroxypropyl Guar Galactomannan is the same as AL-43546. The clinical trial NCT00760045 refers to the drug as AL-43546 Ophthalmic Product, indicating that AL-43546 is an alternative name for this drug candidate.